SCHEMBL3424045

SCHEMBL3424045

O=C1NC(=S)SC1=Cc1ccc(-c2ccccc2C(=O)O)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 1/20 1.00
INSR P06213 3/20 0.69
IGF1R P08069 3/20 0.69
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
PIK3CG P48736 7/20 0.63
ENPP2 Q13822 1/20 0.60
POLB P06746 4/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
PIK3CA P42336 2/20 0.58
PIK3CB P42338 1/20 0.58
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
HSPD1 P10809 1/20 0.54
HSPE1 P61604 1/20 0.54
BRAF P15056 1/20 0.54
ALDH1A1 P00352 1/20 0.54
MAPT P10636 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3424039 1.00 PTP4A3 (1.00) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL30287682 1.00 PTP4A3 (1.00) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL12990075 1.00 PTP4A3 (1.00) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL623775 0.82 IGF1R (1.00) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL622800 0.82 PIK3CG (0.80) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL6090652 0.82 IGF1R (0.74) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL6090645 0.82 IGF1R (0.74) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL622799 0.82 PIK3CG (0.80) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL623774 0.82 IGF1R (1.00) PTP4A3INSRIGF1RMEN1KMT2A
SCHEMBL29910211 0.82 IGF1R (0.74) PTP4A3INSRIGF1RMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220026444-A1 METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2022-01-27 US claimed
EP-3886851-A1 METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) 2021-10-06 EP claimed
CN-113271943-A Method for diagnosing and/or treating acute or chronic liver, kidney or lung diseases 比奥基内生物科学协会合作研究中心 2021-08-17 CN claimed
WO-2020109316-A1 METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2020-06-04 WO claimed
US-12285439-B2 Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2025-04-29 US disclosed
US-20240229041-A2 NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2024-07-11 US disclosed
US-20230265438-A1 NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE (ES) 2023-08-24 US disclosed
EP-4158023-A1 NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) 2023-04-05 EP disclosed
US-20220026444-A1 METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2022-01-27 US disclosed
WO-2021239825-A1 NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL SILENCE THERAPEUTICS GMBH (DE) 2021-12-02 WO disclosed
EP-3886851-A1 METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) 2021-10-06 EP disclosed
CN-113271943-A Method for diagnosing and/or treating acute or chronic liver, kidney or lung diseases 比奥基内生物科学协会合作研究中心 2021-08-17 CN disclosed
WO-2020109316-A1 METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2020-06-04 WO disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240229041-A2 NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL HNF4A, CDK4, CDKL4 PTP4A3 2731/4885INSR 929/4885IGF1R 1049/4885
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PTP4A3 1768/4885INSR 1642/4885IGF1R 522/4885
US-20230265438-A1 NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL HNF4A, CDK4, CDKL4 PTP4A3 2731/4885INSR 929/4885IGF1R 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.